Strides Pharma Science announced a new development agreement between Strides Pharma Global and OINDP specialist CDMO Kenox Pharmaceuticals for “multiple nasal spray products for the US market across diverse therapeutic indications.” The company did not reveal financial details or the products involved in the deal. Earlier this year, Kenox announced that it was adding clinical-scale GMP manufacturing capabilities for inhaled and nasal products at its facility in New Jersey, USA.
Strides Pharma Science Executive Director of Business Development Aditya Kumar commented, “We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain. With continued investments in the capabilities and capacities at our US facility, these products are a natural fit within our strategy to expand into our nasal spray technology domain. Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market strengths allowing us to accelerate our range of nasal spray offerings in the US market.”
Kenox CEO Sitaram Velaga said, “Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price.”
Read the Strides Pharma press release
